Stockscreener 앱 받기
0.812
4.47%
-0.038
시간 외 거래:
.82
0.008
+0.99%
전일 마감가:
$0.85
열려 있는:
$0.8203
하루 거래량:
19,996
Relative Volume:
0.61
시가총액:
$3.17M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-6.67%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.81
$0.85
1주일 범위
$0.75
$0.90
52주 변동 폭
$0.7232
$0.92
Naya Biosciences Stock (NAYA) Company Profile
명칭
Naya Biosciences
전화
(978) 878-9505
주소
5582 BROADCAST COURT, SARASOTA
NAYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| NAYA | 0.812 | 3.17M | 0 | 0 | 0 | 0.00 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Naya Biosciences 주식(NAYA)의 최신 뉴스
NAYA (NAYA Biosciences) Profitability Rank : 2 (As of Jun. 2024) - GuruFocus.com
NAYA Biosciences to Present Translational Insights to - GlobeNewswire
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewswire
INVO Bioscience, Inc. announced that it has received $0.275 million in funding - Marketscreener.com
INVO Bioscience Closes Wisconsin Fertility Institute Acquisition - Marketscreener.com
INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel Invocell System for Use in the Treatment of Infertility - Marketscreener.com
INVO Bioscience, Inc. Announces Appointment of Pressly Ahammed as Director of International Business Development - Marketscreener.com
INVOcell Appoints Yve Lyppens as Director Business Development Asia Pacific - Marketscreener.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
INVO Bioscience, Inc. Announces Grand Opening of "Positib Fertility, an INVO Center" in Monterrey, Mexico on November 1, 2021 - Marketscreener.com
INVO Bioscience Announces the Appointment of Steve Shum as Chief Executive Officer - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a - GlobeNewswire
NAYA (NAYA Biosciences) Enterprise Value : $15.50 Mil (As of Oct. 25, 2024) - GuruFocus.com
Top Premarket Gainers - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma - The Manila Times
The court declared bankruptcy of MPG AgroProduction OÜ - The Manila Times
INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 - Marketscreener.com
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC - Marketscreener.com
INVO Bioscience changes name, trading symbol after merger - Business Observer
INVO Bioscience confirms name change, new trading symbol following NAYA merger - TipRanks
INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences - The Manila Times
CERo Therapeutics, Inc. Provides Corporate Update - The Manila Times
INVO Bioscience (NASDAQ: INVO) Stock Sees Bullish Momentum on Merger News - DRP Journal
INVO Bioscience Completes Merger with NAYA Biosciences - TipRanks
Sarasota fertility company completes merger with bioscience firm - Business Observer
INVO Bioscience merges with NAYA, eyes oncology market - Investing.com
INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA) - The Manila Times
Sify Technologies announces the appointment of Ms. Padmaja Chunduru as Director on the Board - The Manila Times
INVO Bioscience, NAYA Biosciences close merger - TipRanks
INVO Bioscience secures $265,000 through Merchant Cash Advance - Investing.com India
INVO Bioscience faces Nasdaq delisting over share price - Investing.com
INVO Bioscience extends merger agreement with NAYA - Investing.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Sudden doctor departure at Middleton fertility clinic leaves patients unsettled - Madison.com
Naya Biosciences - The Pharma Letter
'We wasted a year': Abrupt shakeup at Wisconsin fertility clinic leaves families scrambling for answers - Milwaukee Journal Sentinel
INVO Bioscience receives Nasdaq compliance extension - Investing.com
Trading the Gap to Win in the Pre-Market - DataDrivenInvestor
Why Is Invo Bioscience (INVO) Stock Up 85% Today? - InvestorPlace
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
INVO Bioscience Seeks Funds After NAYA Misses Deadline - TipRanks
NAYA buys gene therapy company Florida Biotech for $20m - Pharmaceutical Technology
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) - GlobeNewswire
CGT Landscape: Recent Approvals, Deals And 2024 Catalysts - In Vivo
INVO Bioscience Files S-4 Registration and Preliminary - GlobeNewswire
Ten NK cell therapy companies to look out for this year - Labiotech.eu
Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered - Labiotech.eu
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal - PR Newswire
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies - PR Newswire
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement - PR Newswire
INVO Reports Record Third Quarter 2023 Financial Results - PR Newswire
Naya Biosciences (NAYA) 재무 분석
Naya Biosciences (NAYA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.38%
0.43%
자본화:
|
볼륨(24시간):